Nanjing Vazyme Biotech Co Ltd (688105) - Total Liabilities

Latest as of June 2026: CN¥1.03 Billion CNY ≈ $150.58 Million USD

Based on the latest financial reports, Nanjing Vazyme Biotech Co Ltd (688105) has total liabilities worth CN¥1.03 Billion CNY (≈ $150.58 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Nanjing Vazyme Biotech Co Ltd's assets to evaluate the company's liquid asset resilience ratio.

Nanjing Vazyme Biotech Co Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how Nanjing Vazyme Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 688105 total assets.

Nanjing Vazyme Biotech Co Ltd Competitors by Total Liabilities

The table below lists competitors of Nanjing Vazyme Biotech Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Northking Information Technology Co
SHE:002987
China CN¥803.39 Million
EQ Resources Ltd
AU:EQR
Australia AU$115.21 Million
Gestamp Automocion SA
MC:GEST
Spain €7.20 Billion
GIMV NV
BR:GIMB
Belgium €436.25 Million
Progress Software Corporation
NASDAQ:PRGS
USA $1.84 Billion
Grupo Televisa SAB ADR
NYSE:TV
USA $122.08 Billion
Pfeiffer Vacuum Technology AG
F:PFV
Germany €424.22 Million
Republic Bancorp Inc
NASDAQ:RBCAA
USA $5.91 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down Nanjing Vazyme Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 688105 net asset quality score to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.99 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.29 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.22 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nanjing Vazyme Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nanjing Vazyme Biotech Co Ltd (2017–2025)

The table below shows the annual total liabilities of Nanjing Vazyme Biotech Co Ltd from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥1.24 Billion
≈ $180.97 Million
+11.92%
2024-12-31 CN¥1.11 Billion
≈ $161.70 Million
-35.64%
2023-12-31 CN¥1.72 Billion
≈ $251.24 Million
+23.24%
2022-12-31 CN¥1.39 Billion
≈ $203.85 Million
+190.33%
2021-12-31 CN¥479.83 Million
≈ $70.21 Million
+71.81%
2020-12-31 CN¥279.28 Million
≈ $40.87 Million
+124.65%
2019-12-31 CN¥124.31 Million
≈ $18.19 Million
+46.82%
2018-12-31 CN¥84.67 Million
≈ $12.39 Million
+125.34%
2017-12-31 CN¥37.57 Million
≈ $5.50 Million
--

About Nanjing Vazyme Biotech Co Ltd

SHG:688105 China Biotechnology
Market Cap
$1.65 Billion
CN¥11.27 Billion CNY
Market Cap Rank
#6921 Global
#1449 in China
Share Price
CN¥21.79
Change (1 day)
+3.07%
52-Week Range
CN¥13.14 - CN¥25.52
All Time High
CN¥119.29
About

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more